TZDs quickly passed clinical trials and became front-line agents in the treatment of type II diabetes for their robust insulin-sensitizing and glucose-lowering actions, although their popularity has recently decreased in response to safety concerns. Here, INS is linked to type 2 diabetes mellitus.